Skip to main content

Table 1 Clinical characteristics of the study population

From: Longitudinal analysis of healthy colon establishes aspirin as a suppressor of cancer-related epigenetic aging

Characteristic

No. subjects

Time point 1 (t1)a

Time point 2 (t2)b

Aspirin regular usec

Nonuserd

14 (45%)

11 (35%)

Long-term user (≥ 2 year)e

17 (55%)

20 (65%)

Age

50–70 (median 55)

60–80 (median 65)

BMIf

  

 Normal (18.5–25)

16 (52%)

14 (45%)

 High (≥ 26)

15 (48%)

17 (55%)

Polyps

 No polyps

18 (58%)

23 (74%)

 Yes

13 (42%)

8 (26%)

Proximalg

 Tubular adenoma

3 (23%)

1 (12.5%)

 Serrated lesionh

1 (8%)

0 (0%)

 Hyperplastic

1 (8%)

0 (0%)

 Serrated adenoma

0 (0%)

0 (0%)

 Mixed

0 (0%)

1 (12.5%) TA and SA

distali

 Tubular adenoma

4 (31%)

4 (50%)

 Serrated lesion

5 (38%)

0 (0%)

 Hyperplastic

4 (31%)

0 (0%)

 Serrated adenoma

1 (7%)

0 (0%)

 Mixed

0 (0%)

1 (12.5%) TA and HP

 Proximal and distal

0 (0%)

1 (12.5%) TA

  1. aBaseline time point
  2. b10-year follow-up
  3. cRegular use defined as ≥ 2 tablets/week for ≥ 1 month
  4. dNonuser: women who indicated that they did not use the aspirin ≥ 2 tablets/week for ≥ 1 month (“minimum level”)
  5. eLong-term user: women who indicated that they used the aspirin ≥ 2 tablets/week for ≥ 2 years
  6. fBMI: body mass index; height (cm) and weight (kg) were self-reported and BMI was calculated (kg/m2) from these variables
  7. gProximal: cecum
  8. hSerrated lesion: any serrated polyp including hyperplastic and serrated adenoma
  9. iDistal: sigmoid colon